HDAC9 and plasma cell myeloma: It is worth noting that a previous study reported that the combination of HDAC and aminopeptidase inhibitors is highly synergistic in multiple myeloma via the disruption of the NFκB signalling pathway [26], which indicates that our dual inhibitor P1 might be useful as anti-multiple myeloma agent.